Summary
None of the provided claims are supported by the supplied FDA-approved label excerpts, which appear to relate to INVEGA (paliperidone) extended-release tablets rather than Invega Sustenna (paliperidone palmitate) injections. Medication-specific administration/dosing claims and non-label claims (pricing/coverage/programs/patent resources) are not supported by the provided labeling.
Category Scores
Accurate Statements
Unsupported Statements
Invega Sustenna (paliperidone palmitate) retail price without insurance for a single injection can range from approximately $1,200 to $1,500 or more.
Pricing/cash-pay ranges are not present in the supplied label excerpts.
Insurance plans, including Medicare and Medicaid, often provide coverage for Invega Sustenna, substantially reducing out-of-pocket expenses.
Coverage and out-of-pocket expense details are not present in the supplied label excerpts.
Copay or coinsurance for Invega Sustenna depends on the details of an individual's health insurance policy.
Cost-sharing mechanics are not present in the supplied label excerpts.
Pharmaceutical companies may offer patient assistance programs or copay cards to help eligible individuals afford Invega Sustenna.
Patient assistance/copay card program availability is not present in the supplied label excerpts.
Invega Sustenna is an extended-release injectable suspension administered by a healthcare professional.
The provided excerpts do not contain Invega Sustenna-specific formulation/administration text (and appear to concern INVEGA extended-release tablets).
The initial dose of Invega Sustenna is typically given as two injections on the same day.
Invega Sustenna-specific initiation dosing regimen is not present in the supplied label excerpts.
Subsequent doses of Invega Sustenna are usually administered once a month.
Invega Sustenna-specific maintenance dosing frequency is not present in the supplied label excerpts.
The dosage strength prescribed for Invega Sustenna depends on the patient's individual needs and response to treatment.
Dose-selection criteria for Invega Sustenna are not present in the supplied label excerpts.
Other long-acting injectable (LAI) antipsychotics available for schizophrenia treatment include Abilify Maintena (aripiprazole).
Comparative listing of other products is not present in the supplied label excerpts.
Other long-acting injectable (LAI) antipsychotics available for schizophrenia treatment include Haldol Decanoate (haloperidol decanoate).
Comparative listing of other products is not present in the supplied label excerpts.
Other long-acting injectable (LAI) antipsychotics available for schizophrenia treatment include Invega Trinza (paliperidone palmitate).
Comparative listing of other products is not present in the supplied label excerpts.
Other long-acting injectable (LAI) antipsychotics available for schizophrenia treatment include Risperdal Consta (risperidone).
Comparative listing of other products is not present in the supplied label excerpts.
Other long-acting injectable (LAI) antipsychotics available for schizophrenia treatment include Zyprexa Relprevv (olanzapine pamoate).
Comparative listing of other products is not present in the supplied label excerpts.
Each listed LAI antipsychotic has a different active ingredient.
General comparative assertions are not present in the supplied label excerpts.
Each listed LAI antipsychotic has a dosing frequency that differs from the others.
General comparative assertions are not present in the supplied label excerpts.
Each listed LAI antipsychotic has a potential side effect profile that differs from the others.
General comparative assertions are not present in the supplied label excerpts.
Invega Sustenna is a branded medication.
Branding status is not addressed in the supplied label excerpts.
Information regarding Invega Sustenna's patent exclusivity and potential generic competition can be tracked through resources like DrugPatentWatch.com that monitor drug patents and their expiration dates.
Patent-tracking resources/patent exclusivity guidance is not present in the supplied label excerpts.
Patient assistance programs and copay cards for Invega Sustenna are often available through the drug manufacturer or specialized patient support services.
Program availability statements are not present in the supplied label excerpts.
Information regarding eligibility and application processes for Invega Sustenna patient assistance programs and copay cards can typically be found on the manufacturer's official website or by speaking with a healthcare provider or pharmacist.
Eligibility/application instructions for assistance programs are not present in the supplied label excerpts.
Contradictions
Important Omissions
Invega Sustenna-specific FDA-labeled indication(s), dosing/administration details, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, and monitoring—because no Invega Sustenna label sections were provided in the excerpts.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response includes multiple medication-specific administration and dosing schedule claims for Invega Sustenna that are not supported by the provided label excerpts, plus several non-label assertions (pricing/coverage/assistance/patent resources). Without on-label support, there is an elevated risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Noncompliant
Primary Issue
Claims are not supported by the supplied prescribing information (and the excerpts appear to describe INVEGA extended-release tablets rather than Invega Sustenna injections).
Suggested Improvement
Use only claims explicitly present in the FDA-approved Invega Sustenna (paliperidone palmitate) label sections, and omit non-label topics such as pricing/coverage/copay programs/patent-tracking resources unless the label contains such statements.